EP1471147A3 - Method of making a recombinant molecule for the expression of HPV-16 L1 protein - Google Patents

Method of making a recombinant molecule for the expression of HPV-16 L1 protein Download PDF

Info

Publication number
EP1471147A3
EP1471147A3 EP04014651A EP04014651A EP1471147A3 EP 1471147 A3 EP1471147 A3 EP 1471147A3 EP 04014651 A EP04014651 A EP 04014651A EP 04014651 A EP04014651 A EP 04014651A EP 1471147 A3 EP1471147 A3 EP 1471147A3
Authority
EP
European Patent Office
Prior art keywords
hpv
protein
expression
making
recombinant molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04014651A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1471147A2 (en
Inventor
Ian Frazer
Jian Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
CSL Ltd
Original Assignee
University of Queensland UQ
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1471147(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Queensland UQ, CSL Ltd filed Critical University of Queensland UQ
Publication of EP1471147A2 publication Critical patent/EP1471147A2/en
Publication of EP1471147A3 publication Critical patent/EP1471147A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP04014651A 1991-07-19 1992-07-20 Method of making a recombinant molecule for the expression of HPV-16 L1 protein Withdrawn EP1471147A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPK732291 1991-07-19
AUPK732291 1991-07-19
EP92915973A EP0595935B1 (en) 1991-07-19 1992-07-20 Papillomavirus Vaccine
EP02009841A EP1298211B1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of HPV16 Genome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02009841A Division EP1298211B1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of HPV16 Genome

Publications (2)

Publication Number Publication Date
EP1471147A2 EP1471147A2 (en) 2004-10-27
EP1471147A3 true EP1471147A3 (en) 2007-03-21

Family

ID=3775561

Family Applications (5)

Application Number Title Priority Date Filing Date
EP04014651A Withdrawn EP1471147A3 (en) 1991-07-19 1992-07-20 Method of making a recombinant molecule for the expression of HPV-16 L1 protein
EP02009841A Expired - Lifetime EP1298211B1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of HPV16 Genome
EP92915973A Expired - Lifetime EP0595935B1 (en) 1991-07-19 1992-07-20 Papillomavirus Vaccine
EP01126938A Withdrawn EP1207203A3 (en) 1991-07-19 1992-07-20 DNA sequence and papillomavirus vaccine
EP03005929A Expired - Lifetime EP1359156B1 (en) 1991-07-19 1992-07-20 Vaccine against Human Papillomavirus (Type 18)

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP02009841A Expired - Lifetime EP1298211B1 (en) 1991-07-19 1992-07-20 Polynucleotide segment of HPV16 Genome
EP92915973A Expired - Lifetime EP0595935B1 (en) 1991-07-19 1992-07-20 Papillomavirus Vaccine
EP01126938A Withdrawn EP1207203A3 (en) 1991-07-19 1992-07-20 DNA sequence and papillomavirus vaccine
EP03005929A Expired - Lifetime EP1359156B1 (en) 1991-07-19 1992-07-20 Vaccine against Human Papillomavirus (Type 18)

Country Status (16)

Country Link
US (5) US7476389B1 (enExample)
EP (5) EP1471147A3 (enExample)
JP (3) JP3828570B2 (enExample)
KR (1) KR100240480B1 (enExample)
AT (3) ATE234925T1 (enExample)
AU (1) AU651727B2 (enExample)
CA (1) CA2113712C (enExample)
CY (5) CY2598B2 (enExample)
DE (11) DE122007000018I1 (enExample)
DK (3) DK0595935T3 (enExample)
ES (3) ES2194839T3 (enExample)
GE (1) GEP20084431B (enExample)
LU (8) LU91317I2 (enExample)
NL (8) NL300261I1 (enExample)
SG (1) SG48769A1 (enExample)
WO (1) WO1993002184A1 (enExample)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000018I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
DK0647140T3 (da) * 1992-06-25 2008-02-04 Univ Georgetown Papillomavirusvacciner
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE05075369T1 (de) * 1993-03-09 2006-11-16 The University Of Rochester Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
CA2189882C (en) * 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
DE122007000093I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
DE4435907C2 (de) * 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
EP0812358A1 (en) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
SE9501512D0 (sv) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
CA2237224C (en) * 1995-11-15 2006-06-27 Steven Ludmerer Synthetic hpv11 virus-like particles
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2267639C (en) * 1996-10-04 2005-11-22 Merck & Co., Inc. Synthetic hpv16 virus-like particles
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2213841T3 (es) * 1996-12-09 2004-09-01 MERCK & CO., INC. Particulas sinteticas semejantes al virus hpv16.
DE69736779T2 (de) * 1996-12-20 2007-08-16 Merck & Co., Inc. Zusammensetzungen von rekombinanten papillomavirus vakzinen
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
WO1999001557A1 (en) * 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
WO2003103570A2 (en) 2001-08-01 2003-12-18 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
KR20030067873A (ko) * 2002-02-08 2003-08-19 주식회사 유니크 솔레노이드 밸브
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
CA2539703C (en) * 2003-09-25 2011-06-07 Third Wave Technologies, Inc. Detection of human papilloma virus (hpv) utilizing invasive cleavage structure assays
RU2405568C2 (ru) * 2004-09-10 2010-12-10 Асахи Гласс Компани, Лимитед Иммуногенная композиция
US8021992B2 (en) * 2005-09-01 2011-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8080643B2 (en) * 2006-09-05 2011-12-20 Third Wave Technologies, Inc. HPV primers
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
MX344751B (es) * 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
US20100285056A1 (en) * 2008-01-09 2010-11-11 Konkuk University Industrial Cooperation Corp. Baculovirus-Based Vaccines
CN102099053A (zh) 2008-05-26 2011-06-15 卡迪拉保健有限公司 麻疹-人乳头瘤组合疫苗
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
KR101349291B1 (ko) 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
WO2016149384A1 (en) * 2015-03-18 2016-09-22 University Of Massachusetts Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
KR101908438B1 (ko) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
AU2017268144B2 (en) 2016-05-16 2021-07-22 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
EP3458028A1 (en) 2016-05-16 2019-03-27 Infectious Disease Research Institute Pegylated liposomes and methods of use
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
WO2023126589A1 (fr) * 2021-12-29 2023-07-06 Hitachi High-Tech Corporation Methode d'analyse d'images de microbes
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (fr) 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NL8902301A (nl) * 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
WO1992016638A1 (en) 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
DE122007000018I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
DK0647140T3 (da) 1992-06-25 2008-02-04 Univ Georgetown Papillomavirusvacciner
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE05075369T1 (de) 1993-03-09 2006-11-16 The University Of Rochester Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. BROWNE ET AL.: "Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant", J. GEN. VIROL., vol. 69, 1988, pages 1263 - 1273, XP008014046 *
J. ZHOU ET AL.: "Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles", VIROLOGY, vol. 185, 1991, pages 251 - 257, XP008013151 *
J. ZHOU ET AL.: "Increased antibody responses to human papillomavirus type 16 L1 protein expressed by vaccinia virus lacking serine protease inhibitor genes", J. GEN. VIROL., vol. 71, 1990, pages 2185 - 2190, XP000917694 *

Also Published As

Publication number Publication date
NL300312I1 (nl) 2008-02-01
CY2007016I1 (el) 2009-11-04
DE69233639D1 (de) 2006-08-24
ES2279020T3 (es) 2007-08-16
US7939082B2 (en) 2011-05-10
DE69233639T2 (de) 2007-05-31
NL300266I1 (nl) 2007-05-01
DE122007000016I1 (de) 2007-05-24
EP1359156A2 (en) 2003-11-05
DE69232967D1 (de) 2003-04-24
JP2006115849A (ja) 2006-05-11
EP1298211A3 (en) 2003-04-16
DE122007000086I1 (de) 2008-04-17
LU91321I2 (fr) 2007-05-09
LU91317I2 (fr) 2007-04-27
US20070154902A1 (en) 2007-07-05
DK1298211T3 (da) 2006-11-13
LU91387I2 (fr) 2008-02-14
CY2007015I1 (el) 2009-11-04
ATE356142T1 (de) 2007-03-15
US6613557B1 (en) 2003-09-02
ES2267890T3 (es) 2007-03-16
SG48769A1 (en) 1998-05-18
EP1359156B1 (en) 2007-03-07
AU2366692A (en) 1993-02-23
ATE234925T1 (de) 2003-04-15
EP1207203A2 (en) 2002-05-22
CY2007030I1 (el) 2012-01-25
DE122007000023I1 (de) 2007-08-09
EP0595935A1 (en) 1994-05-11
DE122007000017I1 (de) 2007-07-26
NL300261I1 (nl) 2007-05-01
CY2007015I2 (el) 2016-08-31
DE122007000085I1 (de) 2008-03-27
DK1359156T3 (da) 2007-04-10
HK1059271A1 (en) 2004-06-25
LU91315I2 (fr) 2007-04-27
EP1359156A3 (en) 2004-03-24
DE69232967T2 (de) 2003-12-18
CA2113712C (en) 2007-06-12
GEP20084431B (en) 2008-07-25
WO1993002184A1 (en) 1993-02-04
JP4255944B2 (ja) 2009-04-22
KR100240480B1 (ko) 2000-03-02
NL300263I1 (nl) 2007-05-01
DE122007000018I1 (de) 2007-05-24
NL300314I1 (nl) 2008-02-01
EP1471147A2 (en) 2004-10-27
JP3828570B2 (ja) 2006-10-04
EP1207203A3 (en) 2004-04-28
CA2113712A1 (en) 1993-02-04
EP1298211A2 (en) 2003-04-02
LU91385I2 (fr) 2008-02-14
DE122007000019I1 (de) 2007-07-26
JP2004000269A (ja) 2004-01-08
EP0595935B1 (en) 2003-03-19
US20040214331A1 (en) 2004-10-28
DK0595935T3 (da) 2003-07-21
CY2007030I2 (el) 2017-04-05
JPH07505042A (ja) 1995-06-08
LU91386I2 (fr) 2008-02-14
EP0595935A4 (en) 1995-03-29
ATE332973T1 (de) 2006-08-15
DE122007000084I1 (de) 2008-03-27
CY2007016I2 (el) 2009-11-04
EP1298211B1 (en) 2006-07-12
DE69233687D1 (de) 2007-04-19
LU91318I2 (fr) 2007-04-27
US20090252761A1 (en) 2009-10-08
ES2194839T3 (es) 2003-12-01
CY2007034I1 (el) 2012-01-25
NL300314I2 (nl) 2010-03-01
CY2598B2 (en) 2010-03-03
NL300313I1 (nl) 2008-02-01
AU651727B2 (en) 1994-07-28
NL300262I1 (nl) 2007-05-01
US7476389B1 (en) 2009-01-13
NL300260I1 (nl) 2007-05-01
LU91316I2 (fr) 2007-04-27
DE69233687T2 (de) 2007-10-18
US7169585B2 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
EP1471147A3 (en) Method of making a recombinant molecule for the expression of HPV-16 L1 protein
EP0327377A3 (en) Kex2 endoprotease and process for production thereof
ZA951008B (en) N-terminally chemically modificed protein compositions and method
CA2171699A1 (en) Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
NZ503850A (en) April - a novel protein with growth effects
AU586897B2 (en) Thrombin preparations
CA2061382A1 (en) Method for producing cysteine-free peptide
EP2278003A3 (en) Method for controlling the activity of immunologically functional molecule
EP1225225A3 (en) Osteogenic devices
CA2203765A1 (en) Cathepsin o2 protease
IL76107A0 (en) Method of removing n-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
IT8421436A0 (it) Proteina cosi' prodotta. un plasmide ricombinante, un microorganismo trasformante un segmento di polideossiribonucleotide, un procedimento per produrre una proteina biologicamente attiva e la
AU1094892A (en) Improved activation of recombinant proteins
AU6806187A (en) Pseudorabies virus mutants minus g92 polypeptide
AU3055495A (en) Recombinant mersacidin and a method for production
IL95057A (en) Recombinant gene coding for a protein possessing urate oxidase activity
AU7474787A (en) Secretion of heterologous proteins from yeast
IE902388L (en) Vasoactive intestinal peptide analogs.
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
EP0295679A3 (en) Physiologically-active novel peptides
EP1241882A3 (en) Duplication controlling method, duplication controlling apparatus, recording medium, and program embodied on computer-readable medium
HK112693A (en) Immunogenic recombinant yeast expression product and method for purifying it
EP0185433A3 (en) Retro-inverted peptides analogues of bradykinin potentiator bpp 5a
IL114597A0 (en) Method of converting a hydrophobic derivative of a polypeptide into its native form
CA2158583A1 (en) Pharmaceutical Composition in the Form of a Kit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040623

AC Divisional application: reference to earlier application

Ref document number: 1298211

Country of ref document: EP

Kind code of ref document: P

Ref document number: 0595935

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHOU, JIAN

Inventor name: FRAZER, IAN

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070384

Country of ref document: HK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20070213BHEP

Ipc: C12N 15/37 20060101AFI20040907BHEP

Ipc: C07K 14/025 20060101ALI20070213BHEP

Ipc: C12N 15/63 20060101ALI20070213BHEP

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20071221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070384

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120607